Schneider Kai Markus, Wirtz Theresa H, Kroy Daniela, Albers Stefanie, Neumann Ulf Peter, Strowig Till, Sellge Gernot, Trautwein Christian
Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Department of Visceral and Transplantation Surgery, University Hospital RWTH Aachen, Aachen, Germany.
Case Rep Gastroenterol. 2018 Feb 21;12(1):76-84. doi: 10.1159/000481937. eCollection 2018 Jan-Apr.
infection (CDI) represents one of the most common healthcare-associated infections. Due to increasing numbers of recurrences and therapy failures, CDI has become a major disease burden. Studies have shown that fecal microbiota transplantation (FMT) can both be a safe and highly efficacious therapy for patients with therapy-refractory CDI. However, patients undergoing solid organ transplantation are at high risk for CDI due to long-term immunosuppression, previous antibiotic therapy, and proton pump inhibitor use. Additionally, these patients may be especially prone to adverse events related to FMT. Here, we report a successful FMT in a patient with severe therapy-refractory CDI after liver transplantation.
艰难梭菌感染（CDI）是最常见的医疗保健相关感染之一。由于复发和治疗失败的病例不断增加，CDI已成为一项重大的疾病负担。研究表明，粪便微生物群移植（FMT）对于治疗难治性CDI患者而言，既安全又高效。然而，由于长期免疫抑制、先前的抗生素治疗以及质子泵抑制剂的使用，实体器官移植患者发生CDI的风险很高。此外，这些患者可能特别容易出现与FMT相关的不良事件。在此，我们报告了1例肝移植术后发生严重治疗难治性CDI患者成功接受FMT的病例。
